NEW YORK, March 12 – Aaron Davidson, previously a member of Eli Lilly’s corporate development team, has been named vice president of business development at SYN X Pharma, the company said Monday.
SYN X, a Toronto-based proteomics company is looking to launch deals for therapeutics and diagnostics stemming from the company’s initiatives.
During his nine-year tenure with Eli Lilly, Davidson completed a number of multi-million dollar in- licensing, out-partnering, and distribution deals in the areas of epilepsy, Parkinson's disease, and oncology.
At SYN X Davidson will be responsible for developing and accelerating strategic alliances for the company’s Proteomics Discovery Platform, which can be used to identify protein targets for the development of new drugs and antibody-based diagnostics.
The company is currently developing diagnostics for diabetes, cardiovascular and central nervous system diseases.